GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer

Ni, Yun‐Bi; Tsang, Julia Y. S.; Shao, Mumin; Chan, Siu‐Ki; Cheung, Sai‐Yin; Tong, Joanna H.; To, Ka‐Fai; Tse, Gary M.

doi:10.1007/s10549-017-4645-2

Cited by 63 publications

(97 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, its sensitivity ranges between 5 and 74% [9]. It is regrettable that we could not evaluate GATA-3 expression which has been reported to show higher sensitivity than GCDFP-15 [10]. Positive IHC staining for synaptophysin suggested a neuroendocrine tumor.…”

Section: Discussionmentioning

confidence: 91%

Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy

et al. 2020

View full text Add to dashboard Cite

Patients with cancer of unknown primary (CUP) are generally treated with chemotherapy. Bone marrow involvement suggests an advanced stage, and CUP with disseminated carcinomatosis of the bone marrow (DCBM) appears to have a dismal prognosis. However, our case of CUP with DCBM was successfully treated with a sequence of endocrine therapy over a long period. A woman presenting with low back pain was found to have multiple bone metastasis without an identifiable primary tumor on imaging studies. Blood tests revealed anemia and thrombocytopenia. A bone marrow biopsy was performed and showed relatively uniform small cells, strongly positive for estrogen receptor and progesterone receptor expression. We considered chemotherapy to be risky due to bicytopenia and an aromatase inhibitor, letrozole, was initiated. The patient's symptoms and laboratory findings gradually improved and bone lesions almost disappeared on FDG-PET/CT after 1 year of treatment. After 2 years on letrozole, hemoglobin levels and platelet counts had been gradually decreasing. Although she had no symptoms and no significant changes were observed on a CT scan, disease progression was highly likely. Thus, second-line treatment with fulvestrant and palbociclib was commenced, and hemoglobin levels and platelet counts were restored to within the normal ranges. She currently continues to receive fulvestrant and palbociclib over a year later. CUP complicated with DCBM might be metastatic occult breast cancer, and endocrine therapy can be a valuable treatment option if tumors express hormone receptors.

show abstract

Section: Discussionmentioning

confidence: 91%

Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The highest MVD mean value was obtained for luminal B breast cancers (95.33) while the lowest value was obtained for the luminal A type (30). The mean value for TNBCs ranged between 62.66 and 40.…”

Section: Resultsmentioning

confidence: 90%

Microvessel Density and Mammaglobin A Expression as Prognostic Markers in Molecular Types of Breast Cancer

Jitariu¹,

Ceauşu²,

Meche³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

Increased microvessel density (MVD) values in breast cancer correlate with tumor growth and progression while mammaglobin (MGB) expression in tumor cells is associated with a favorable prognosis. We aim to evaluate and correlate MVD values with MGB expression in molecular types of breast cancer specimens and to determine their utility as prognostic biological markers. A number of 52 breast cancer specimens were included in the study. Specimens were processed for routine histopathological diagnosis followed by the molecular classification by means of estrogen (ER), progesterone (PR) and HER2 immunohistochemical reactions. After performing immunohistochemistry for CD34 and MGB, MVD evaluation was made using the �hot spot� method for each case and MGB was scored between 0 (negative) and +3 (strong positive) depending on the intensity and distribution of the staining. MGB expression in tumor cells and MVD mean values were extremely variable. The greatest MVD mean values were obtained in luminal B followed by HER2, luminal A and triple negative breast cancer (TNBC) (95.33, 69, 62, and 40, respectively). MGB expression in the tumor cells generally ranged from mild to weak and was strong only in a few invasive ductal carcinoma cases. In cases with TNBCs the expression of MGB in tumor cells was weak and focal or negative. This variability was noticed between the molecular types of breast cancers and even within the same molecular type. In a restricted number of cases, MGB positive tumors were associated with low MVD values while the negative cases were characterized by increased MVD mean values. The variable results we obtained regarding the correlation between MVD and MGB in breast cancer specimens may indicate a rather restricted use of MVD/MGB in estimating breast cancer patients� prognosis.

show abstract

“…On the other hand, considering the history of breast cancer, the immunopro le of breast cancer such as ER, PR, HER2, GATA3 and GCDFP15, should be used to con rm the origin from breast cancer metastasis. Previous studies have demonstrated that GATA3 and GCDFP15 expression were positively associated with breast carcinoma and breast cancer metastasis [15,16].GATA3 is superior to GCDFP15 in determining the breast origin [17,18]. Ghias et al [5] reported that thyroid metastases cells were positive for ER, GATA3, and were negative for GCDFP, TTF-1, TG and calcitonin.…”

Section: Discussionmentioning

confidence: 98%

Thyroid metastases from breast carcinoma: case report and review of literature

Wang¹,

Zhou²,

Yu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Rationale: The thyroid is a rare site for distant metastases from breast carcinoma. The incidence of thyroid metastases in fine needle aspiration biopsy (FNAB) was less than 0.2%.Patient concerns: We report a case of 54-year-old woman with a history of breast carcinoma presented with diffuse scattered microcalcifications in thyroid and enlarged bilateral cervical lymph nodes detected on ultrasound (US). Physical examination of the patient revealed stiff and enlarged thyroid lobes.Diagnoses: FNAB and immunohistochemistry （IHC）of the thyroid lesion confirmed the thyroid metastases from breast cancer.Interventions and outcomes: Due to the comorbidities of breast carcinoma metastases to the right axillary, cervical lymph nodes and left chest wall, the patient received chemotherapy. After a follow-up of 10 months, the patient was alive without any new distant metastases.Lessons: Our case highlights that thyroid metastases should be considered in a patient combined with thyroid lesions and a history of breast carcinoma. IHC played an important role in differentiating thyroid metastases from primary thyroid cancer.

show abstract

GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer

Cited by 63 publications

References 48 publications

Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy

Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy

Microvessel Density and Mammaglobin A Expression as Prognostic Markers in Molecular Types of Breast Cancer

Thyroid metastases from breast carcinoma: case report and review of literature

Contact Info

Product

Resources

About